Milk thistle (Silybum marianum) for the therapy of liver disease

American Journal of Gastroenterology

Volumn 93, Issue 2, 1998, Pages 139-143

  Flora, Kenneth ^a   Hahn, Martin ^a   Rosen, Hugo ^a   Benner, Kent ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIOXIDANT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; BUTYROPHENONE DERIVATIVE; CALCIUM; FREE RADICAL; IRON CHELATING AGENT; MALATHION; PHALLOIDIN; PHENOTHIAZINE DERIVATIVE; PLACEBO; SCAVENGER; SILIBININ; SILYBUM MARIANUM EXTRACT; SILYMARIN; STABILIZING AGENT; TUMOR PROMOTER;

ALCOHOL LIVER DISEASE; ALTERNATIVE MEDICINE; AMANITA PHALLOIDES; CALCIUM METABOLISM; CHRONIC HEPATITIS; CHRONIC LIVER DISEASE; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG INDUCED DISEASE; HUMAN; LIPID PEROXIDATION; LIVER CELL; LIVER CIRRHOSIS; LIVER DISEASE; LIVER INJURY; MAST CELL; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROTEIN SYNTHESIS; REVIEW; TUMOR PROMOTION; VIRUS HEPATITIS;

HUMANS; LIVER DISEASES; PHYTOTHERAPY; PLANT EXTRACTS; SILYMARIN;

EID: 0032008339     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1572-0241.1998.00139.x     Document Type: Review

References (51)

1. 1. Brevoort P. The U.S. botanical market - An overview. Herbalgram 1996;36:49-57.
2. 2. Flora KD, Rosen HR, Benner KG. The use of naturopathic remedies for chronic liver disease. Am J Gastroenterol 1996;91:2654-5.
3. 3. Hobbs C. Milk thistle: The liver herb. Capitola, CA: Botanical Press, 1992.
4. 4. Greive M. A modern herbal, vol. 2. New York: Dover Publications, 1981.
5. 5. Foster S. Milk thistle: Silybum marianum. Austin, TX: American Botanical Council, No. 305, 1991.
6. 6. Harnisch G, Stolze H. Silybum marianum: Mariendistel. In: Bewaehrte Pflanzendrogen in Wissenschaft und Medizin. Notamed Verlag, 1983: 203-15.
7. 7. Madaus G. Lehrbuch der biologischen Heilmittel, vol I. Leipzig: Georg Thieme Verlag, 1938:830-6.
8. 8. Cowley G. Herbal warning. Newsweek, May 6, 1996:60-8.
9. 9. Herbal roulette. Consumer Reports, Nov 1995:195-705.
10. 10. Willard T. Textbook of advanced herbology. Calgary, Alberta, Canada: Wild Rose College of Natural Healing Ltd., 1992.
11. 11. Lorenz D, Lucker PW, Mennicke WH, et al. Meth find exp Clin Pharmacol 1984;6:655.
12. 12. Barzaghi N, Crema F, Gatti G, et al. Pharmacokinetic studies in IdB 1016, a silybin-phosphatidylcholine complex, in healthy human subjects. Eur J Drug Metab Pharmacokinet 1990;15:333-8.
13. 13. Orlando R, Fragasso A, Lampertico M, et al. Med Sci Res 1990;18: 861.
14. 14. Gatti G, Perucca E. Plasma concentrations of free and conjugated silybin after oral intake of a silybin-phosphatidylcholine complex (silipide) in healthy volunteers. Internat J Clin Pharmacol Therapeutics 1994;32:614-7.
15. 15. Flory PJ, Krug G, Lorenz D, et al. Planta Med 1980;38:227.
16. 16. Buelles H, Buelles J, Krumbiegel G, et al. Untersuchungen zur Verstoffwechselung und zur Ausscheidung von Silybin bei der Ratte. Arzneimittel-Forsch 1971;21:1206-8.
17. 17. Mennicke WH. Dtsch Apoth Ztg 1975;115:1205.
18. 18. Lorenz D, Mennicke WH, Behrendt W. Untersuchungen zur Elimination von Silymarin bei cholezystektomierten Patienten. 2. Mitteilung: Biliaere Elimination nach mehrfacher oraler Gabe. Planta Med 1982; 45:216-23.
19. 19. Schandalik R, Gatti G, Perucca E. Pharmacokinetics of silybin in bile following administration of silipide and silymarin in cholecystectomy patients. Arzneimittel-Forschung 1992;42:964-8.
20. 20. Vogel G. A peculiarity among flavenoids - Silymarin, a compound active on the liver. Proceedings of the International Bioflavonoid Symposium, Munich, FRG 1981:472.
21. 21. Mira L, Silva M, Manso CF. Scavenging of reactive oxygen species by silibinin dihemisuccinate. Biochem Pharmacol 1994;48:753-9.
22. 22. Bosisio E, Benelli C, Pirola O. Effect of the flavanolignans of Silybum marianum L. on lipid peroxidation in rat liver microsomes and freshly isolated hepatocytes. Pharmacol Res 1992;25:147-54.
23. 23. Carini R, Comoglio A, Albano E, et al. Lipid peroxidation and irreversible damage in the rat hepatocyte model: Protection by the silybin-phospholipid complex IdB 1016. Biochem Pharmacol 1992;43:2111-5.
24. 24. Valenzuela A, Barria T, Guerra R, et al. Inhibitory effect of the flavonoid silymarin on the erythrocyte hemolysis induced by phenylhydrazine. Biochem Biophys Res Commun 1985;126:712-8.
25. 25. Takahara E, Ohta S, Hirobe M. Stimulatory effects of Silibinin on the DNA synthesis in partially hepatectomized rat livers: Non-response in hepatoma and other malignant cell lines. Biochem Pharmacol 1986; 35:538-41.
26. 26. Pietrangelo A, Borella F, Casalgrandi G, et al. Antioxidant activity of silybin in vivo during long-term iron overload in rats. Gastroenterology 1995;109:1941-9.
27. 27. Agrawal R, Katiyar SK, Lundgren DW, et al. Inhibitory effect of silymarin, an anti-hepatotoxic flavonoid, on 12-O-tetradecanoylphorbol-13-acetate-induced epidermal ornithine decarboxylase activity and mRNA in SENCAR mice. Carcinogenesis, 1994;15:1099-1103.
28. 28. Lecomte J. Proprietes pharmacologiques generales de la silybine et de la silymarine chez le rat. Arch Internat de Pharmacodynamie et de Therapie 1975;214:165-76.
29. 29. Hakova H, Misurova E. The effect of silymarin and gamma radiation on nucleic acids in rat organs. J Pharm Pharmacol 1993;45:910-2.
30. 30. Plomteux G, Albert A, Heusghem C. Hepatoprotector action of silymarin in human acute viral hepatitis. Int Res Commun Syst 1977;5: 259.
31. 31. Magliulo E, Gagliardi B, Fiori GP. Zur Wirkung von Silymarin bei der Behandlung der akuten Virushepatitis. Med Klin 1978;73:1060-5.
32. 32. Cavalieri S. Kontrollierte klinische Pruefung von Legalon. Gazz Med Ital 1974;133:628.
33. 33. Desplaces A, Choppin J, Vogel G, et al. The effects of silymarin on experimental phalloidine poisoning. Arzneimittel-Forschung 1975;25: 89-96.
34. 34. Firmmer VM, Kroker R. Phalloidin-antagonisten. 1. Mitteilung: Wirkung von Silybin-derivaten an der isoliert perfundierten Rattenleber. Arzneimittel-Forschung 1975;25:394-6.
35. 35. Vogel G, Trost W, Braatz R, et al. Untersuchungen zu Pharmakodynamik, Angriffspunkt und Wirkungsmechanismus von Silymarin, dem antihepatotoxischen Prinzip aus Silybum mar. (L.) gaertn. Arzneimittel-Forsch 1975;25:82-9.
36. 36. Vogel G, Tuchweber B, Trost W, et al. Protection by silybinin against Amanita phalloides intoxication in beagles. Toxicol Appl Pharmacol 1984;73:355-62.
37. 37. Vogel G. Natural substances with effects on the liver. In: New natural products and plant drugs with pharmacological, biological or therapeutical activity. New York: Springer-Verlag, 1977:2651-65.
38. 38. Hruby C. Silibinin in the treatment of deathcap fungus poisoning. Forum 1984;6:23-6.
39. 39. Floersheim GL, Weber O, Tschumi P, et al. Poisoning by the deathcap fungus (Amanita phalloides): Prognostic factors and therapeutic measures. Schweiz Med Wochenschrift 1982;112:1164-77.
40. 40. Boari C, Baldi E, Rizzoli O, et al. Silymarin in the protection against exogenous noxae. Drugs Exp Clin Res 1981;7:115-20.
41. 41. Szilard S, Szentgyorgyi D, Demeter I. Protective effect of Legalon in workers exposed to organic solvents. Acta Med Hung 1988;45:249-56.
42. 42. Palasciano G, Portinacasa P, et al. The effect of silymarin on plasma levels of malondialdehyde in patients receiving long-term treatment with psychotropic drugs. Curr Ther Res 1994;55:537-45.
43. 43. Saba P, Galeone F, Salvadorini F, et al. Effetti terapeutici della silimarina nelle epatopatie croniche indotte da psicofarmaci. Gaz Med It 1976;135:236-51.
44. 44. Martines G, Piva M, Copponi V, et al. La silimarina in gravidanza e nel trattamento contraccettivo ormonale. Rilievi ematochimici ed ultrastrutturali su modello sperimentale. Archivio Pr Le Scienze Mediche 1979;136:443-54.
45. 45. Fintelmann V. Postoperatives Verhalten der Serumcholinesterase und anderer Leberenzyme, Med Klin 1973;68:809.
46. 46. Feher J, Deak G, Muzes G, et al. Hepatoprotective activity of silymarin (Legalon) therapy in patients with chronic liver disease. Orvosi Hetilap 1989;130:2723-7.
47. 47. Salmi HA, Sarna S. Effect of silymarin on chemical, functional and morphological alterations of the liver: A double-blind study. Scand J Gastroenterol 1982;17:517-21.
48. 48. Fintelmann V, Albert A. Nachweis der therapeutischen Wirksamkeit von Legalon bei toxischen Lebererkrankungen im Doppelblindversuch. Therapiewoche 1980;30:5589-94.
49. 49. Ferenci P, Dragosics B, Dittrich H, et al. Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. J Hepatol 1989;9:105-13.
50. 50. Albrecht M, Frerick H, et al. Therapy of toxic liver pathologies with Legalon. Z Klin Med 1992;47:87-92.
51. 51. Kiesewetter E, Leodolter I, Thaler H. Ergebnisse zweier Doppelblindstudien zur Wirksamkeit von Silymarin bei chronischer Hepatitis. Leber Magen Darm 1977;7:318-23.